Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

AI can accurately measure hair loss severity in alopecia areata.

This article reviews how SALT scores are used in clinical trials for alopecia areata and provides patient images to help clinicians understand and apply these scores in practice; it reports no new clinical results.

This study concluded that achieving 80% or more scalp hair, corresponding to a SALT score of ≤20, represents a clinically meaningful treatment success for patients with alopecia areata experiencing ≥50% hair loss.

This study found that trichoscopy is essential for evaluating the severity of alopecia areata and predicting treatment responses, contributing to more personalized patient management.

This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.

Severe hair loss (androgenetic alopecia) is linked to higher risk of heart disease (cardiovascular atherosclerosis).

This study developed and validated an objective dermoscopic severity score for evaluating female pattern hair loss, which may serve as a supplementary outcome measure in therapeutic trials.

In this study, researchers found that among 7,761 patients with androgenetic alopecia, behaviors such as insufficient sleep, poor dietary habits, alcohol consumption, heavy physical labor, and specific hairstyling choices were associated with increased severity of hair loss.

This study investigated individuals with androgenetic alopecia and found that serum iron and ferritin levels are associated with obstructive sleep apnea severity, suggesting the importance of considering iron profiles in managing the condition.

This study investigated 130 patients and found a significant inverse correlation between copper content and the copper/zinc ratio in hair samples and the extent of coronary artery disease, while zinc content alone showed no significant relationship with disease extent.

This article presents a computer imaging algorithm that may automate and enhance the Severity of Alopecia Tool scoring for alopecia areata through texture analysis of pediatric images.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This meta-regression analysis observed a slightly negative but nonsignificant correlation between vitamin D levels and the severity of alopecia areata, suggesting a complex relationship that requires further investigation.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This study developed a handheld card to simplify the calculation of the SALT score for assessing alopecia areata severity, noting that while it accelerates the process, formal validation against existing methods is still needed.

This study found that at Week 52, baricitinib resulted in significant hair regrowth for many patients with severe alopecia areata, with 41.6% on the higher dose achieving substantial improvement in scalp hair loss, though some may need longer treatment for optimal benefit.

This study found that using planimetric surface area measurement might be a useful supplementary method to improve the accuracy of SALT scoring in alopecia areata, particularly for scores S1 to S3.

This study found that plasma Claudin 3 levels were linked to alopecia areata severity among patients compared to healthy controls.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.

This study found that both Th1 and Th2 cytokine markers were elevated in the serum and skin of patients with alopecia areata, with Th2 markers more closely linked to disease severity.

This study found that programmed death-ligand 1 (PD-L1) levels correlated with the severity of alopecia areata, suggesting its potential as an indicator and possible target for new treatments.

This study found that while vitamin D deficiency is not the sole cause of alopecia areata, it may worsen the disease, suggesting supplementation could help in pediatric cases.

There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.

This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.

This study suggests that distinct alopecia scoring systems measure percent hair loss as a common underlying feature, with strong correlations observed between different types of hair loss assessments.